ReviewJournal of the American Heart Association2025
Research Progress of BMAL1 in Heart Failure.
Review in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TNFR2 Agonism as a Sex-Specific Therapy for Novel Osteoarthritis-Induced Cardiac Dysfunction.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure represents the terminal stage of cardiovascular disease, with cardiac remodeling as a key pathological feature. As a core circadian clock gene, brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (BMAL1) not only regulates circadian rhythms but also plays a critical role in cardiac remodeling. Studies have shown that BMAL1 deficiency leads to myocardial metabolic dysfunction, cardiomyocyte hypertrophy, activation of the inflammatory response, fibrosis, and impaired cardiac function, thereby promoting the onset and progression of heart failure. This review systematically summarizes the mechanisms by which BMAL1 influences heart failure, with a focus on its regulatory roles in metabolism, inflammation, and fibrosis. Furthermore, we explore clinical translational potential and future prospects of correcting circadian rhythm disruption and chronotherapy in heart failure, aiming to provide new insights and directions for its treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.